Structure and Immune Recognition of the HIV Glycan Shield

Annual Review of Biophysics

Volumn 47, Issue , 2018, Pages 499-523

  Crispin, Max ^a   Ward, Andrew B ^b   Wilson, Ian A ^b  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

broadly neutralizing antibody; EM structure; glycan composition; glycosylation; viral glycoprotein; X ray structure

Indexed keywords

CD4 ANTIGEN; GLYCAN; GLYCOPEPTIDE; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 41; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEUTRALIZING ANTIBODY; VIRUS ENVELOPE PROTEIN;

ANTIBODY RESPONSE; ANTIGEN RECOGNITION; BIOSYNTHESIS; COMPARATIVE STUDY; CRYOELECTRON MICROSCOPY; CRYSTAL STRUCTURE; DEGLYCOSYLATION; DRUG DESIGN; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ISOTHERMAL TITRATION CALORIMETRY; LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY; NONHUMAN; OLIGOMERIZATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN ENGINEERING; PROTEIN GLYCOSYLATION; PROTEIN QUATERNARY STRUCTURE; REVIEW; STOICHIOMETRY; VIRUS PARTICLE; VIRUS SPIKE; X RAY CRYSTALLOGRAPHY;

EID: 85047543847     PISSN: 1936122X     EISSN: 19361238     Source Type: Book Series    
DOI: 10.1146/annurev-biophys-060414-034156     Document Type: Review

References (152)

1. Agirre J, Davies GJ, Wilson KS, Cowtan KD. 2017. Carbohydrate structure: the rocky road to automation. Curr. Opin. Struct. Biol. 44:39-47
2. Arnold JN, Radcliffe CM, Wormald MR, Royle L, Harvey DJ, et al. 2004. The glycosylation of human serum IgD and IgE and the accessibility of identified oligomannose structures for interaction with mannan-binding lectin. J. Immunol. 173:6831-40
3. Baba TW, Liska V, Hofmann-Lehmann R, Vlasak J, Xu W, et al. 2000. Human neutralizingmonoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat. Med. 6:200-6
4. Balazs AB, Chen J, Hong CM, Rao DS, Yang L, Baltimore D. 2011. Antibody-based protection against HIV infection by vectored immunoprophylaxis. Nature 481:81-84
5. Bartesaghi A, Merk A, Borgnia MJ, Milne JL, Subramaniam S. 2013. Prefusion structure of trimeric HIV-1 envelope glycoprotein determined by cryo-electron microscopy. Nat. Struct. Mol. Biol. 20:1352-57
6. Behrens AJ, CrispinM. 2017. Structural principles controlling HIV envelope glycosylation. Curr. Opin. Struct. Biol. 44:125-33
7. Behrens AJ, Harvey DJ, Milne E, Cupo A, Kumar A, et al. 2017. Molecular architecture of the cleavagedependent mannose patch on a soluble HIV-1 envelope glycoprotein trimer. J. Virol. 91:e01894-16
8. Behrens AJ, Vasiljevic S, Pritchard LK, Harvey DJ, Andev RS, et al. 2016. Composition and antigenic effects of individual glycan sites of a trimeric HIV-1 envelope glycoprotein. Cell Rep. 14:2695-706
9. Binley JM, Sanders RW, Clas B, Schuelke N, Master A, et al. 2000. A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure. J. Virol. 74:627-43
10. Binley JM, Sanders RW, Master A, Cayanan CS, Wiley CL, et al. 2002. Enhancing the proteolytic maturation of human immunodeficiency virus type 1 envelope glycoproteins. J. Virol. 76:2606-16
11. Blattner C, Lee JH, SliepenK, Derking R, FalkowskaE, et al. 2014. Structural delineation of a quaternary, cleavage-dependent epitope at the gp41-gp120 interface on intact HIV-1 Env trimers. Immunity 40:669-80
12. Blixt O, Head S, Mondala T, Scanlan C, Huflejt ME, et al. 2004. Printed covalent glycan array for ligand profiling of diverse glycan binding proteins. PNAS 101:17033-38
13. Bonomelli C, Doores KJ, Dunlop DC, Thaney V, Dwek RA, et al. 2011. The glycan shield of HIV is predominantly oligomannose independently of production system or viral clade. PLOS ONE 6:e23521
14. Briney B, Sok D, Jardine JG, Kulp DW, Skog P, et al. 2016. Tailored immunogens direct affinity maturation toward HIV neutralizing antibodies. Cell 166:1459-70.e11
15. Bryan MC, Fazio F, Lee HK, Huang CY, Chang A, et al. 2004. Covalent display of oligosaccharide arrays in microtiter plates. J. Am. Chem. Soc. 126:8640-41
16. Burton DR, Ahmed R, Barouch DH, Butera ST, Crotty S, et al. 2012. A blueprint for HIV vaccine discovery. Cell Host Microbe 12:396-407
17. Burton DR, Hangartner L. 2016. Broadly neutralizing antibodies to HIV and their role in vaccine design. Annu. Rev. Immunol. 34:635-59
18. Burton DR, Mascola JR. 2015. Antibody responses to envelope glycoproteins in HIV-1 infection. Nat. Immunol. 16:571-76
19. Calarese DA, Scanlan CN, Zwick MB, Deechongkit S, Mimura Y, et al. 2003. Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science 300:2065-71
20. Cale EM, Gorman J, Radakovich NA, Crooks ET, Osawa K, et al. 2017. Virus-like particles identify an HIV V1V2 apex-binding neutralizing antibody that lacks a protruding loop. Immunity 46:777-91
21. Cao L, Diedrich JK, Kulp DW, Pauthner M, He L, et al. 2017. Global site-specific N-glycosylation analysis of HIV envelope glycoprotein. Nat. Commun. 8:14954
22. Chang SH, Han JL, Tseng SY, Lee HY, Lin CW, et al. 2010. Glycan array on aluminum oxide-coated glass slides through phosphonate chemistry. J. Am. Chem. Soc. 132:13371-80
23. Chang VT, Crispin M, Aricescu AR, Harvey DJ, Nettleship JE, et al. 2007. Glycoprotein structural genomics: solving the glycosylation problem. Structure 15:267-73
24. Coss KP, Vasiljevic S, Pritchard LK, Krumm SA, Glaze M, et al. 2016. HIV-1 glycan density drives the persistence of the mannose patch within an infected individual. J. Virol. 90:11132-44
25. Crispin M, Doores KJ. 2015. Targeting host-derived glycans on enveloped viruses for antibody-based vaccine design. Curr. Opin. Virol. 11:63-69
26. Crispin M, Ritchie GE, Critchley AJ, Morgan BP, Wilson IA, et al. 2004. Monoglucosylated glycans in the secreted human complement component C3: implications for protein biosynthesis and structure. FEBS Lett. 566:270-74
27. Crispin M, Stuart DI, Jones EY. 2007. Building meaningful models of glycoproteins. Nat. Struct. Mol. Biol. 14:354
28. Crooks ET, Osawa K, Tong T, Grimley SL, Dai YD, et al. 2017. Effects of partially dismantling the CD4 binding site glycan fence of HIV-1 Envelope glycoprotein trimers on neutralizing antibody induction. Virology 505:193-209
29. Crooks ET, Tong T, Chakrabarti B, Narayan K, Georgiev IS, et al. 2015. Vaccine-elicited tier 2 HIV-1 neutralizing antibodies bind to quaternary epitopes involving glycan-deficient patches proximal to the CD4 binding site. PLOS Pathog. 11:e1004932
30. Cutalo JM, Deterding LJ, Tomer KB. 2004. Characterization of glycopeptides from HIV-I(SF2) gp120 by liquid chromatography mass spectrometry. J. Am. Soc. Mass Spectrom. 15:1545-55
31. de Taeye SW, Ozorowski G, Torrents de la Pena A, Guttman M, Julien J-P, et al. 2015. Immunogenicity of stabilizedHIV-1 envelope trimers with reduced exposure of non-neutralizing epitopes. Cell 163:1702-15
32. Decroly E, Vandenbranden M, Ruysschaert JM, Cogniaux J, JacobGS, et al. 1994. The convertases furin and PC1 can both cleave the human immunodeficiency virus (HIV)-1 envelope glycoprotein gp160 into gp120 (HIV-1 SU) and gp41 (HIV-I TM). J. Biol. Chem. 269:12240-47
33. Dimitrov DS. 2010. Therapeutic antibodies, vaccines and antibodyomes. mAbs 2:347-56
34. Domann PJ, Pardos-Pardos AC, Fernandes DL, Spencer DI, Radcliffe CM, et al. 2007. Separation-based glycoprofiling approaches using fluorescent labels. Proteomics 7 (Suppl. 1):70-76
35. Doores KJ. 2015. The HIV glycan shield as a target for broadly neutralizing antibodies. FEBS J. 282:4679-91
36. Doores KJ, Bonomelli C, Harvey DJ, Vasiljevic S, Dwek RA, et al. 2010. Envelope glycans of immunodeficiency virions are almost entirely oligomannose antigens. PNAS 107:13800-5
37. Ekiert DC, Bhabha G, Elsliger MA, Friesen RH, Jongeneelen M, et al. 2009. Antibody recognition of a highly conserved influenza virus epitope. Science 324:246-51
38. Emini EA, Schleif WA, Nunberg JH, Conley AJ, Eda Y, et al. 1992. Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody. Nature 355:728-30
39. Escolano A, Dosenovic P, Nussenzweig MC. 2017. Progress toward active or passive HIV-1 vaccination. J. Exp. Med. 214:3-16
40. Falkowska E, Le KM, Ramos A, Doores KJ, Lee JH, et al. 2014. Broadly neutralizing HIV antibodies define a glycan-dependent epitope on the prefusion conformation of gp41 on cleaved envelope trimers. Immunity 40:657-68
41. Freund NT, Horwitz JA, Nogueira L, Sievers SA, Scharf L, et al. 2015. A new glycan-dependent CD4-binding site neutralizing antibody exerts pressure on HIV-1 in vivo. PLOS Pathog. 11:e1005238
42. Fukui S, Feizi T, Galustian C, Lawson AM, Chai W. 2002. Oligosaccharide microarrays for highthroughput detection and specificity assignments of carbohydrate-protein interactions. Nat. Biotechnol. 20:1011-17
43. Garces F, Lee JH, de Val N, de la Pena AT, Kong L, et al. 2015. Affinity maturation of a potent family of HIV antibodies is primarily focused on accommodating or avoiding glycans. Immunity 43:1053-63
44. Garces F, Sok D, Kong L, McBride R, Kim HJ, et al. 2014. Structural evolution of glycan recognition by a family of potent HIV antibodies. Cell 159:69-79
45. Geissner A, Seeberger PH. 2016. Glycan arrays: from basic biochemical research to bioanalytical and biomedical applications. Annu. Rev. Anal. Chem. 9:223-47
46. Go EP, Ding H, Zhang S, Ringe RP, Nicely N, et al. 2017. Glycosylation benchmark profile for HIV-1 envelope glycoprotein production based on eleven Env trimers. J. Virol. 91:e02428-16
47. Go EP, Herschhorn A, Gu C, Castillo-Menendez L, Zhang S, et al. 2015. Comparative analysis of the glycosylation profiles of membrane-anchored HIV-1 envelope glycoprotein trimers and soluble gp140. J. Virol. 89:8245-57
48. Go EP, Liao H-X, Alam SM, Hua D, Haynes BF, Desaire H. 2013. Characterization of host-cell line specific glycosylation profiles of early transmitted/founder HIV-1 gp120 envelope proteins. J. Proteome Res. 12:1223-34
49. Green RS, Stone EL, Tenno M, Lehtonen E, Farquhar MG, Marth JD. 2007. Mammalian N-glycan branching protects against innate immune self-recognition and inflammation in autoimmune disease pathogenesis. Immunity 27:308-20
50. Gristick HB, von Boehmer L, West AP Jr., SchamberM, Gazumyan A, et al. 2016. Natively glycosylated HIV-1 Env structure reveals new mode for antibody recognition of the CD4-binding site. Nat. Struct. Mol. Biol. 23:906-15
51. Guenaga J, Dubrovskaya V, de Val N, Sharma SK, Carrette B, et al. 2015. Structure-guided redesign increases the propensity of HIV Env to generate highly stable soluble trimers. J. Virol. 90:2806-17
52. Guenaga J, Garces F, de Val N, Stanfield RL, Dubrovskaya V, et al. 2017. Glycine substitution at helix-to-coil transitions facilitates the structural determination of a stabilized subtype C HIV envelope glycoprotein. Immunity 46:792-803
53. Guttman M, Garcia NK, Cupo A, Matsui T, Julien JP, et al. 2014. CD4-induced activation in a soluble HIV-1 Env trimer. Structure 22:974-84
54. Hessell AJ, Rakasz EG, Poignard P, Hangartner L, Landucci G, et al. 2009. Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLOS Pathog. 5:e1000433
55. Hessell AJ, Rakasz EG, Tehrani DM, Huber M, Weisgrau KL, et al. 2010. Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L. J. Virol. 84:1302-13
56. Hu JK, Crampton JC, Cupo A, Ketas T, van Gils MJ, et al. 2015. Murine antibody responses to cleaved soluble HIV-1 envelope trimers are highly restricted in specificity. J. Virol. 89:10383-98
57. Huang J, Kang BH, Pancera M, Lee JH, Tong T, et al. 2014. Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interface. Nature 515:138-42
58. Jardine JG, Julien J-P, Menis S, Ota T, Kalyuzhniy O, et al. 2013. Rational HIV immunogen design to target specific germline B cell receptors. Science 340:711-16
59. Jardine JG, KulpDW, Havenar-DaughtonC, Sarkar A, Briney B, et al. 2016. HIV-1 broadly neutralizing antibody precursor B cells revealed by germline-targeting immunogen. Science 351:1458-63
60. Jardine JG, Ota T, Sok D, Pauthner M, Kulp DW, et al. 2015. Priming a broadly neutralizing antibody response to HIV-1 using a germline-targeting immunogen. Science 349:156-61
61. Jardine JG, Sok D, Julien J-P, Briney B, Sarkar A, et al. 2016. Minimally mutated HIV-1 broadly neutralizing antibodies to guide reductionist vaccine design. PLOS Pathog. 12:e1005815
62. Julien J-P, Cupo A, Sok D, Stanfield RL, Lyumkis D, et al. 2013. Crystal structure of a soluble cleaved HIV-1 envelope trimer. Science 342:1477-83
63. Julien J-P, Lee JH, Cupo A, Murin CD, Derking R, et al. 2013. Asymmetric recognition of the HIV-1 trimer by broadly neutralizing antibody PG9. PNAS 110:4351-56
64. Julien J-P, Lee JH, Ozorowski G, Hua Y, Torrents de la Pena A, et al. 2015. Design and structure of two HIV-1 clade C SOSIP.664 trimers that increase the arsenal of native-like Env immunogens. PNAS 112:11947-52
65. Julien J-P, Lee PS, Wilson IA. 2012. Structural insights into key sites of vulnerability onHIV-1 Env and influenza HA. Immunol. Rev. 250:180-98
66. Julien J-P, Sok D, Khayat R, Lee JH, Doores KJ, et al. 2013. Broadly neutralizing antibody PGT121 allosterically modulates CD4 binding via recognition of the HIV-1 gp120 V3 base and multiple surrounding glycans. PLOS Pathog. 9:e1003342
67. Khayat R, Lee JH, Julien J-P, Cupo A, Klasse PJ, et al. 2013. Structural characterization of cleaved, soluble HIV-1 envelope glycoprotein trimers. J. Virol. 87:9865-72
68. Kirchdoerfer RN, Cottrell CA, Wang N, Pallesen J, Yassine HM, et al. 2016. Pre-fusion structure of a human coronavirus spike protein. Nature 531:118-21
69. Klasse PJ, LaBranche CC, Ketas TJ, Ozorowski G, Cupo A, et al. 2016. Sequential and simultaneous immunization of rabbits with HIV-1 envelope glycoprotein SOSIP.664 trimers from Clades A, B and C. PLOS Pathog. 12:e1005864
70. Klein F, Gaebler C, Mouquet H, Sather DN, Lehmann C, et al. 2012. Broad neutralization by a combination of antibodies recognizing the CD4 binding site and a new conformational epitope on the HIV-1 envelope protein. J. Exp. Med. 209:1469-79
71. Kong L, He L, de Val N, Vora N, Morris CD, et al. 2016. Uncleaved prefusion-optimized gp140 trimers derived from analysis of HIV-1 envelope metastability. Nat. Commun. 7:12040
72. Kong L, Lee JH, Doores KJ, Murin CD, Julien J-P, et al. 2013. Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120. Nat. Struct. Mol. Biol. 20:796-803
73. Kong L, Torrents de la Pena A, Deller MC, Garces F, Sliepen K, et al. 2015. Complete epitopes for vaccine design derived from a crystal structure of the broadly neutralizing antibodies PGT128 and 8ANC195 in complex with an HIV-1 Env trimer. Acta Crystallogr. D Biol. Crystallogr. 71:2099-108
74. Kwong PD, Wyatt R, Desjardins E, Robinson J, Culp JS, et al. 1999. Probability analysis of variational crystallization and its application to gp120, the exterior envelope glycoprotein of type 1 human immunodeficiency virus (HIV-1). J. Biol. Chem. 274:4115-23
75. Lawson AM, Hounsell EF, Stoll MS, Feeney J, Chai WG, et al. 1991. Characterisation of minor tetrato hepta-saccharides O-linked to human meconium glycoproteins by t.l.c.-m.s. microsequencing of neoglycolipid derivatives in conjunction with conventional m.s. and 1H-n.m.r. spectroscopy. Carbohydr. Res. 221:191-208
76. Lee JH, Andrabi R, Su C-Y, Yasmeen A, Julien J-P, et al. 2017. A broadly neutralizing antibody targets the dynamic HIV envelope trimer apex via a long, rigidified, and anionic β-hairpin structure. Immunity 46:690-702
77. Lee JH, de Val N, LyumkisD, Ward AB. 2015. Model building and refinement of a natively glycosylated HIV-1 Env protein by high-resolution cryoelectron microscopy. Structure 23:1943-51
78. Lee JH, OzorowskiG, Ward AB. 2016. Cryo-EM structure of a native, fully glycosylated, cleaved HIV-1 envelope trimer. Science 351:1043-48
79. Leonard CK, Spellman MW, Riddle L, Harris RJ, Thomas JN, Gregory TJ. 1990. Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells. J. Biol. Chem. 265:10373-82
80. Li X, Mooney P, Zheng S, Booth CR, Braunfeld MB, et al. 2013. Electron counting and beam-induced motion correction enable near-atomic-resolution single-particle cryo-EM. Nat. Methods 10:584-90
81. Li Y, Migueles SA, Welcher B, Svehla K, Phogat A, et al. 2007. Broad HIV-1 neutralization mediated by CD4-binding site antibodies. Nat. Med. 13:1032-34
82. Liu Y, Pan J, Cai Y, Grigorieff N, Harrison SC, Chen B. 2017. Conformational states of a soluble, uncleaved HIV-1 envelope trimer. J. Virol. 91:e00175-17
83. Liu Y, Pan J, Jenni S, Raymond DD, Caradonna T, et al. 2017. CryoEM structure of an influenza virus receptor-binding site antibody-antigen interface. J. Mol. Biol. 429:1829-39
84. Loke I, Kolarich D, Packer NH, Thaysen-Andersen M. 2016. Emerging roles of protein mannosylation in inflammation and infection. Mol. Aspects Med. 51:31-55
85. LyumkisD, Julien J-P, de Val N, Cupo A, PotterCS, et al. 2013. Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimer. Science 342:1484-90
86. Mascola JR, Lewis MG, Stiegler G, Harris D, VanCott TC, et al. 1999. Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J. Virol. 73:4009-18
87. McCoy LE, Burton DR. 2017. Identification and specificity of broadly neutralizing antibodies against HIV. Immunol. Rev. 275:11-20
88. McCoy LE, Falkowska E, Doores KJ, Le K, Sok D, et al. 2015. Incomplete neutralization and deviation from sigmoidal neutralization curves forHIV broadly neutralizingmonoclonal antibodies. PLOS Pathog. 11:e1005110
89. McCoy LE, van Gils MJ, Ozorowski G, Messmer T, Briney B, et al. 2016. Holes in the glycan shield of the native HIV envelope are a target of trimer-elicited neutralizing antibodies. Cell Rep. 16:2327-38
90. McLellan JS, Pancera M, Carrico C, Gorman J, Julien J-P, et al. 2011. Structure ofHIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature 480:336-43
91. Medina-Ramírez M, Garces F, Escolano A, Skog P, de Taeye SW, et al. 2017. Design and crystal structure of a native-like HIV-1 envelope trimer that engages multiple broadly neutralizing antibody precursors in vivo. J. Exp. Med. 214:2573-90
92. Mizuochi T, Spellman MW, Larkin M, Solomon J, Basa LJ, Feizi T. 1988. Carbohydrate structures of the human-immunodeficiency-virus (HIV) recombinant envelope glycoprotein gp120 produced in Chinese-hamster ovary cells. Biochem. J. 254:599-603
93. Moldt B, Rakasz EG, Schultz N, Chan-Hui PY, Swiderek K, et al. 2012. Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo. PNAS 109:18921-25
94. Moulard M, Decroly E. 2000. Maturation of HIV envelope glycoprotein precursors by cellular endoproteases. Biochim. Biophys. Acta 1469:121-32
95. Ozorowski G, Pallesen J, de Val N, Lyumkis D, Cottrell CA, et al. 2017. Open and closed structures reveal allostery and pliability in the HIV-1 envelope spike. Nature 547:360-63
96. Pabst M, Chang M, Stadlmann J, Altmann F. 2012. Glycan profiles of the 27 N-glycosylation sites of the HIV envelope protein CN54gp140. Biol. Chem. 393:719-30
97. Pallesen J, Murin CD, de Val N, Cottrell CA, Hastie KM, et al. 2016. Structures of Ebola virus GP and sGP in complex with therapeutic antibodies. Nat Microbiol 1:16128
98. Pallesen J, WangN, Corbett KS, Wrapp D, Kirchdoerfer RN, et al. 2017. Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen. PNAS 114:E7348-57
99. PanceraM, Shahzad-ul-Hussan S, Doria-Rose NA, McLellan JS, Bailer RT, et al. 2013. Structural basis for diverse N-glycan recognition by HIV-1-neutralizing V1-V2-directed antibody PG16. Nat. Struct. Mol. Biol. 20:804-13
100. Pancera M, Zhou T, Druz A, Georgiev IS, Soto C, et al. 2014. Structure and immune recognition of trimeric pre-fusion HIV-1 Env. Nature 514:455-61
101. Panico M, Bouche L, Binet D, O'Connor MJ, Rahman D, et al. 2016. Mapping the complete glycoproteome of virion-derived HIV-1 gp120 provides insights into broadly neutralizing antibody binding. Sci. Rep. 6:32956
102. Parren PW, Marx PA, Hessell AJ, Luckay A, Harouse J, et al. 2001. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J. Virol. 75:8340-47
103. Pejchal R, Doores KJ, Walker LM, Khayat R, Huang P-S, et al. 2011. A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. Science 334:1097-103
104. Peng W, de Vries RP, Grant OC, Thompson AJ, McBride R, et al. 2017. Recent H3N2 viruses have evolved specificity for extended, branched human-type receptors, conferring potential for increased avidity. Cell Host Microbe 21:23-34
105. Pietzsch J, Gruell H, Bournazos S, Donovan BM, Klein F, et al. 2012. A mouse model for HIV-1 entry. PNAS 109:15859-64
106. Pritchard LK, Harvey DJ, Bonomelli C, Crispin M, Doores KJ. 2015. Cell-and protein-directed glycosylation of native cleaved HIV-1 envelope. J. Virol. 89:8932-44
107. Pritchard LK, Spencer DI, Royle L, Bonomelli C, Seabright GE, et al. 2015. Glycan clustering stabilizes themannose patch ofHIV-1 and preserves vulnerability to broadly neutralizing antibodies. Nat. Commun. 6:7479
108. Pritchard LK, Spencer DI, Royle L, Vasiljevic S, Krumm SA, et al. 2015. Glycan microheterogeneity at the PGT135 antibody recognition site onHIV-1 gp120 reveals amolecular mechanism for neutralization resistance. J. Virol. 89:6952-59
109. Pritchard LK, Vasiljevic S, Ozorowski G, Seabright GE, Cupo A, et al. 2015. Structural constraints determine the glycosylation of HIV-1 envelope trimers. Cell Rep. 11:1604-13
110. Pugach P, Ozorowski G, Cupo A, Ringe R, Yasmeen A, et al. 2015. A native-like SOSIP.664 trimer based on an HIV-1 subtype B env gene. J. Virol. 89:3380-95
111. Rademacher TW, Parekh RB, Dwek RA. 1988. Glycobiology. Annu. Rev. Biochem. 57:785-838
112. Reeves PJ, Callewaert N, Contreras R, Khorana HG. 2002. Structure and function in rhodopsin: highlevel expression of rhodopsin with restricted and homogeneous N-glycosylation by a tetracyclineinducible N-acetylglucosaminyltransferase I-negative HEK293S stable mammalian cell line. PNAS 99:13419-24
113. Ringe RP, OzorowskiG, Rantalainen K, Struwe WB, Matthews K, et al. 2017. Reducing V3 antigenicity and immunogenicity on soluble, native-like HIV-1 Env SOSIP trimers. J. Virol. 91:e00677-17
114. Ringe RP, Sanders RW, Yasmeen A, Kim HJ, Lee JH, et al. 2013. Cleavage strongly influences whether soluble HIV-1 envelope glycoprotein trimers adopt a native-like conformation. PNAS 110:18256-61
115. Ringe RP, Yasmeen A, Ozorowski G, Go EP, Pritchard LK, et al. 2015. Influences on the design and purification of soluble, recombinant native-likeHIV-1 envelope glycoprotein trimers. J. Virol. 89:12189-210
116. Rudd PM, Dwek RA. 1997. Glycosylation: heterogeneity and the 3D structure of proteins. Crit. Rev. Biochem. Mol. Biol. 32:1-100
117. Sanders RW, Derking R, Cupo A, Julien J-P, Yasmeen A, et al. 2013. A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies. PLOS Pathog. 9:e1003618
118. Sanders RW, Moore JP. 2017. Native-like Env trimers as a platform forHIV-1 vaccine design. Immunol. Rev. 275:161-82
119. Sanders RW, Vesanen M, Schuelke N, Master A, Schiffner L, et al. 2002. Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1. J. Virol. 76:8875-89
120. Sanders RW, Wilson IA, Moore JP. 2016. HIV's Achilles' Heel. Sci. Am. 315:50-55
121. Scanlan CN, Pantophlet R, Wormald MR, Ollmann Saphire E, Stanfield R, et al. 2002. The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of α1→2 mannose residues on the outer face of gp120. J. Virol. 76:7306-21
122. Scharf L, Scheid JF, Lee JH, West AP, Chen C, et al. 2014. Antibody 8ANC195 reveals a site of broad vulnerability on the HIV-1 envelope spike. Cell Rep. 7:785-95
123. Scheid JF, MouquetH, FeldhahnN, SeamanMS, Velinzon K, et al. 2009. Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature 458:636-40
124. Scheid JF, Mouquet H, Feldhahn N, Walker BD, Pereyra F, et al. 2009. A method for identification of HIV gp140 binding memory B cells in human blood. J. Immunol. Methods 343:65-67
125. Scheres SH. 2012. RELION: implementation of a Bayesian approach to cryo-EM structure determination. J. Struct. Biol. 180:519-30
126. Scheres SH. 2016. Processing of structurally heterogeneous cryo-EM data inRELION. Methods Enzymol. 579:125-57
127. Sharma SK, de Val N, Bale S, Guenaga J, Tran K, et al. 2015. Cleavage-independentHIV-1 Env trimers engineered as soluble native spike mimetics for vaccine design. Cell Rep. 11:539-50
128. Shibata R, Igarashi T, Haigwood N, Buckler-White A, Ogert R, et al. 1999. Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. Nat. Med. 5:204-10
129. SokD, Doores KJ, Briney B, LeKM, Saye-Francisco KL, et al. 2014. Promiscuous glycan site recognition by antibodies to the high-mannose patch of gp120 broadens neutralization of HIV. Sci. Transl. Med. 6:236ra63
130. Sok D, Pauthner M, Briney B, Lee JH, Saye-Francisco KL, et al. 2016. A prominent site of antibody vulnerability on HIV envelope incorporates a motif associated with CCR5 binding and its camouflaging glycans. Immunity 45:31-45
131. Steichen JM, KulpDW, Tokatlian T, Escolano A, Dosenovic P, et al. 2016. HIV vaccine design to target germline precursors of glycan-dependent broadly neutralizing antibodies. Immunity 45:483-96
132. Stevens J, Blixt O, Tumpey TM, Taubenberger JK, Paulson JC, Wilson IA. 2006. Structure and receptor specificity of the hemagglutinin from an H5N1 influenza virus. Science 312:404-10
133. Stevens J, Corper AL, Basler CF, Taubenberger JK, Palese P, Wilson IA. 2004. Structure of the uncleaved human H1 hemagglutinin from the extinct 1918 influenza virus. Science 303:1866-70
134. Stewart-JonesGB, Soto C, LemminT, Chuang GY, Druz A, et al. 2016. Trimeric HIV-1-Env structures define glycan shields from Clades A, B, and G. Cell 165:813-26
135. van Gils MJ, van den Kerkhof TL, Ozorowski G, Cottrell CA, Sok D, et al. 2016. An HIV-1 antibody from an elite neutralizer implicates the fusion peptide as a site of vulnerability. Nat Microbiol 2:16199
136. Veesler D, Campbell MG, Cheng A, Fu CY, Murez Z, et al. 2013. Maximizing the potential of electron cryomicroscopy data collected using direct detectors. J. Struct. Biol. 184:193-202
137. Vinothkumar KR, Henderson R. 2016. Single particle electron cryomicroscopy: trends, issues and future perspective. Q. Rev. Biophys. 49:e13
138. Walker LM, Burton DR. 2010. Rational antibody-based HIV-1 vaccine design: current approaches and future directions. Curr. Opin. Immunol. 22:358-66
139. Walker LM, Huber M, Doores KJ, Falkowska E, Pejchal R, et al. 2011. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 477:466-70
140. Walker LM, Phogat SK, Chan-Hui PY, Wagner D, Phung P, et al. 2009. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326:285-89
141. Ward AB, Sali A, Wilson IA. 2013. Integrative structural biology. Science 339:913-15
142. Ward AB, Wilson IA. 2017. The HIV-1 envelope glycoprotein structure: nailing down a moving target. Immunol. Rev. 275:21-32
143. Wei X, Decker JM, Wang S, Hui H, Kappes JC, et al. 2003. Antibody neutralization and escape by HIV-1. Nature 422:307-12
144. Wibmer CK, Gorman J, AnthonyCS, Mkhize NN, Druz A, et al. 2016. Structure of anN276-dependent HIV-1 neutralizing antibody targeting a rare V5 glycan hole adjacent to the CD4 binding site. J. Virol. 90:10220-35
145. Willey RL, Shibata R, Freed EO, Cho MW, Martin MA. 1996. Differential glycosylation, virion incorporation, and sensitivity to neutralizing antibodies of human immunodeficiency virus type 1 envelope produced from infected primary T-lymphocyte and macrophage cultures. J. Virol. 70:6431-36
146. Wilson IA, Skehel JJ, Wiley DC. 1981. Structure of the haemagglutinin membrane glycoprotein of influenza virus at 3Å resolution. Nature 289:366-73
147. Wyatt R, Kwong PD, Desjardins E, Sweet RW, Robinson J, et al. 1998. The antigenic structure of the HIV gp120 envelope glycoprotein. Nature 393:705-11
148. Wyatt R, Sodroski J. 1998. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science 280:1884-88
149. Yasmeen A, Ringe R, Derking R, Cupo A, Julien J-P, et al. 2014. Differential binding of neutralizing and non-neutralizing antibodies to native-like soluble HIV-1 Env trimers, uncleaved Env proteins, and monomeric subunits. Retrovirology 11:41
150. Zhou T, Doria-Rose NA, Cheng C, Stewart-Jones GBE, Chuang GY, et al. 2017. Quantification of the impact of the HIV-1-glycan shield on antibody elicitation. Cell Rep. 19:719-32
151. Zhou T, Zhu J, Wu X, Moquin S, Zhang B, et al. 2013. Multidonor analysis reveals structural elements, genetic determinants, and maturation pathway for HIV-1 neutralization by VRC01-class antibodies. Immunity 39:245-58
152. Zhu X, Borchers C, Bienstock RJ, Tomer KB. 2000. Mass spectrometric characterization of the glycosylation pattern of HIV-gp120 expressed in CHO cells. Biochemistry 39:11194-204